Tag Archive for: Paxlovid

Pfizer Inc. Chief Executive Officer Albert Bourla said on Monday he had tested positive for COVID-19 and was experiencing very mild symptoms.

Revenue from the antiviral pill, Paxlovid, exceeded market estimates by more than $1 billion, while vaccine sales surged 20%, helping the drugmaker reaffirm the combined 2022 revenue forecast of $54 billion.

U.S. President Joe Biden celebrated his recovery from COVID-19 on Wednesday with an appeal to Americans to get vaccinated and a comparison of his mild symptoms and work-from-home performance to the more serious case experienced by his predecessor.

With just a very small amount of raw sewage and a new analysis technique, researchers can determine the genetic mixture of SARS-CoV-2 variants in the community and detect new variants up to 14 days before they start showing up on patients’ nasal swabs, according to a new report; A sizable proportion of older patients may be taking medications that interact with Paxlovid, Pfizer Inc’s antiviral treatment for COVID-19, according to a new report.

The agency revised its EUA to authorize state-licensed pharmacists to prescribe Paxlovid to eligible patients, with certain limitations to ensure appropriate patient assessment and prescribing of Paxlovid.

The U.S. Food and Drug Administration said on Wednesday it had authorized state-licensed pharmacists to prescribe Pfizer Inc’s (PFE.N) COVID-19 pill to eligible patients to help improve access to the treatment.

Pfizer said it submitted a New Drug Application for Paxlovid to the FDA for the treatment of COVID-19 in vaccinated and unvaccinated people at high risk for progression to severe illness.

People in socially and economically disadvantaged regions are about half as likely to receive an oral antiviral COVID-19 pill than residents of wealthier zip codes, according to a U.S. government study published on Tuesday.

Pfizer Inc. said on Tuesday the company would halt enrollment in a trial for its COVID-19 antiviral drug, Paxlovid, in standard-risk patients after a study revealed the treatment was not effective in reducing symptoms in that group.

Pfizer Inc.’s (PFE.N) antiviral treatment Paxlovid reduces COVID-19 hospitalization and death rates in vaccinated and unvaccinated patients 65 years and older, according to a new study in Israel conducted during the rise of the Omicron variant of the coronavirus.